Cardiogeni PLC Stock Price

OFEX:CGNI Community·UK£8.0m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

CGNI Share Price Performance

UK£0.09

-0.51 (-85.00%)

UK£0.09

-0.51 (-85.00%)

UK£0.09

Sat, 1 Nov 25

Share PriceUK£0.09

CGNI Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Excellent balance sheet with acceptable track record.

2 Risks

2 Rewards

View Full Analysis

Cardiogeni PLC Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

: 0.012
: 100.00%
: 14.07%
: 0%

View Full Analysis

About CGNI

Founded: 2007
Employees: 3
CEO: Trevor Reginald
WebsiteView website: cardiogeni.com

Cardiogeni PLC, a clinical stage biotechnology company, develops heart failure medicines. Its lead product is CLXR-001, a patented engineered cellular medicine, which has completed Phase II clinical trial to treat heart failure patients during coronary artery bypass grafting surgery. The company also develops CLXR-002 and CLXR-003 for heart failure with minimally invasive delivery; and CLXR-004 for use in combination with LVAD device to treat sever heart failure orphan disease indication. The company was founded in 2007 and is headquartered in Stratford-upon-Avon, the United Kingdom.